Brookstone Capital Management Cassava Sciences Inc Transaction History
Brookstone Capital Management
- $6.01 Billion
- Q3 2024
A detailed history of Brookstone Capital Management transactions in Cassava Sciences Inc stock. As of the latest transaction made, Brookstone Capital Management holds 17,753 shares of SAVA stock, worth $42,784. This represents 0.01% of its overall portfolio holdings.
Number of Shares
17,753
Previous 17,753
-0.0%
Holding current value
$42,784
Previous $219,000
138.36%
% of portfolio
0.01%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding SAVA
# of Institutions
207Shares Held
14MCall Options Held
2.98MPut Options Held
6.57M-
Black Rock Inc. New York, NY3.22MShares$7.76 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.52MShares$6.08 Million0.0% of portfolio
-
State Street Corp Boston, MA1.16MShares$2.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.01MShares$2.43 Million0.0% of portfolio
-
Gallacher Capital Management LLC Lone Tree, CO580KShares$1.4 Million7.83% of portfolio
About CASSAVA SCIENCES INC
- Ticker SAVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,097,900
- Market Cap $96.6M
- Description
- Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...